Oncology and Therapy最新文献

{"title":"Clinical Burden of Recurrent Disease in High-Risk Endometrial Cancer.","authors":"Kalé Kponee-Shovein, Vimalanand S Prabhu, Yan Song, Lei Chen, Mu Cheng, Yeran Li, Yezhou Sun, Annalise Hilts, Qi Hua, Jasmine Lichfield, Linda Duska","doi":"10.1007/s40487-025-00352-4","DOIUrl":"https://doi.org/10.1007/s40487-025-00352-4","url":null,"abstract":"<p><strong>Introduction: </strong>Disease-free survival (DFS) is commonly a primary endpoint in clinical trials of investigational therapies for early stage and/or high-risk endometrial cancer and may be indicative of therapeutic benefit prior to maturity of overall survival (OS) data; however, its role as a predictor of OS in high-risk endometrial cancer is unknown. Therefore, this study estimates the individual-level correlation between DFS and OS and the association between recurrent disease and OS in patients with high-risk endometrial cancer receiving adjuvant chemotherapy.</p><p><strong>Methods: </strong>Medicare beneficiaries with high-risk endometrial cancer who underwent surgery followed by adjuvant chemotherapy were identified from Surveillance, Epidemiology, and End Results data (2007-2019). OS and DFS from adjuvant chemotherapy initiation were estimated by Kaplan-Meier (KM) analyses; correlation was evaluated using Kendall's τ rank correlation. Multivariable Cox models were used to compare OS between recurrent and nonrecurrent patients at three landmark points and over the follow-up period.</p><p><strong>Results: </strong>Among 771 patients, 250 (32.4%) experienced recurrence (median follow-up 3.6 years). Median OS was not reached (5-year OS 72.7%); median DFS was 7.9 years (5-year DFS 58.1%). A positive correlation between DFS and OS was observed [Kendall's τ = 0.83; 95% confidence interval (CI) 0.79‒0.86; p < 0.001]. Across landmark points, recurrent patients had 3.8-5.2-fold higher risk of mortality (all p < 0.001). During follow-up, patients with recurrence had a higher risk of mortality than those without (hazard ratio 7.9; 95% CI 5.7‒10.8; p < 0.001).</p><p><strong>Conclusions: </strong>The findings of this study suggest that DFS may be a useful surrogate for OS in high-risk endometrial cancer, though validation in trial-level meta-analyses is needed, and highlight the substantial burden associated with recurrent disease, as evidenced by the four-fold to eight-fold higher risk of mortality across comparative assessments of OS. Effective novel therapies are needed to reduce the considerable burden of disease recurrence in this population.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144620763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutrition in Oncology: Overcoming Challenges to Optimize the Patient Journey from Prehabilitation to Rehabilitation.","authors":"Stanislaw Klek, Alessandro Laviano, Hervé Chrostek, Diana Cardenas","doi":"10.1007/s40487-025-00358-y","DOIUrl":"https://doi.org/10.1007/s40487-025-00358-y","url":null,"abstract":"<p><p>Patients with cancer are likely to be more malnourished than patients treated in other specialties, with many remaining at high nutritional risk prior to surgery or medical treatment. Malnutrition in patients with cancer can result in suboptimal clinical outcomes, and is linked to post-operative complications and reduced mortality, along with increased dose-limiting and treatment side effects. In addition, many medical treatments have gastrointestinal side effects which can further compromise the nutritional status of the patient. However, early patient assessment and proactive management of malnutrition using medical nutrition can have a positive impact on a patient's physiological parameters and functional status, while helping to support their metabolic and dietary needs during their cancer journey. A European Masterclass for Nutrition in Oncology which brought together 50 practitioners, took place on 10-11 October 2024 in Prague, Czech Republic, and aimed to provide an overview of nutrition as the cornerstone of cancer treatment, the use of nutritional prehabilitation in surgery and medical oncology, and optimization of the patient journey with nutrition, including rehabilitation. This paper provides a summary of the content presented, along with insights gained from attendees during four interactive workshop sessions.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144609879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical Guidance on the Clinical Management of Ocular Adverse Events Associated with Belantamab Mafodotin for Patients with Relapsed/Refractory Multiple Myeloma: Latin American Expert Panel Recommendations.","authors":"Vânia Hungria, Virginia Abello Polo, Ariel Corzo, Edvan Q Crusoe, Michel E Farah, Natália A Iutaka, Gracia A Martinez, Aline G Ramírez Alvarado, Simón Romano-Bucay, Patricio G Schlottmann, Cristian M Seehaus, Jorge C Torres Flores, Angelo Maiolino","doi":"10.1007/s40487-025-00354-2","DOIUrl":"https://doi.org/10.1007/s40487-025-00354-2","url":null,"abstract":"<p><p>Multiple myeloma is a significant cause of mortality worldwide, and although changes in the treatment landscape have improved outcomes overall, many patients become refractory to standard therapies. In Latin America, outcomes are especially poor, further compounded by access and equality barriers. Belantamab mafodotin is a novel antibody-drug conjugate, targeting anti-B-cell maturation antigen. Two recent phase 3 trials, DREAMM-7 and DREAMM-8, have demonstrated notable efficacy with belantamab mafodotin combination regimens in patients with relapsed/refractory multiple myeloma. Ocular adverse events were also observed in these studies, as anticipated with antibody-drug conjugates containing monomethyl auristatin F. If belantamab mafodotin is approved for use in clinical practice, healthcare professionals will need clear, region-appropriate guidance on the management of ocular adverse events. A multidisciplinary panel of experts from Argentina, Brazil, Colombia, and Mexico was established, comprising 13 specialists in hematology/oncology and ophthalmology. The panel established a set of practical recommendations to address key clinical questions relating to identification of ocular events, management strategies, multidisciplinary collaboration, and patient-centric care. These recommendations were developed through detailed discussion, review of available evidence, and experience in clinical trials, and are intended to support healthcare professionals across Latin America in the treatment of patients with relapsed/refractory multiple myeloma.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144561450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Safety of the Transition to Generic Imatinib in Patients with Gastrointestinal Stromal Tumours.","authors":"Joris M van Sabben, Maud B A van der Kleij, Evelyne Roets, Renaud L M Tissier, Dorieke E M van Balen, Alwin D R Huitema, Ingrid M E Desar, Anna K L Reyners, Hans Gelderblom, Neeltje Steeghs","doi":"10.1007/s40487-025-00353-3","DOIUrl":"https://doi.org/10.1007/s40487-025-00353-3","url":null,"abstract":"<p><strong>Introduction: </strong>Following patent expiration of branded imatinib (Glivec®), all Dutch patients with gastrointestinal stromal tumours (GIST) switched from Glivec to generic forms. Following this switch, many patients reported new symptoms. Therefore, we conducted this observational study to assess safety of generic imatinib among patients with GIST in the Netherlands.</p><p><strong>Methods: </strong>We included patients with GIST from four hospitals that switched from Glivec to generic imatinib. Within these patients, adverse events (AEs) without the switch to a generic were compared with AEs after the switch using a self-controlled case series design. The reference group was formed by the subset of patients who used imatinib for at least 1 year prior to the switch. As potential causes of increased AEs, we reviewed excipients and analysed plasma trough levels from 1 year prior to 1 year after the switch.</p><p><strong>Results: </strong>In total, 201 patients switched to three generics: Accord® (n = 107), Amarox® (n = 81), and Sandoz® (n = 13). In the reference group (n = 150), 21.3% experienced new AEs, compared with 29.9-34.6% in the different generic groups. All patients that switched to Amarox (odds ratio 2.3; 95% confidence interval (CI): 1.2-4.5) and females that switched to Accord (odds ratio 2.7; 95% CI: 1.1-7.0) experienced a significant increase in AEs. Plasma trough levels were similar among all different formulations. Apart from titanium dioxide in Amarox, no additional excipients were used in any generic form.</p><p><strong>Conclusions: </strong>The transition to generic imatinib in Dutch patients with GIST was safe. After switching to generic imatinib, up to 34.6% of patients experienced new AEs, compared with 21.3% in the reference group, indicating that many AEs may have been mistakenly attributed to the switch. The small increase in AEs that we found was unlikely due to pharmacokinetics or excipients. Therefore, we argue that the nocebo effect, where negative expectations about treatment lead to worsened symptoms, played a large role.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144545401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in the Optimization of CAR-T-Cell-Based Therapeutic Approaches to Enhance Antitumor Efficacy in Glioblastoma Treatment.","authors":"Lidia Gatto, Vincenzo Di Nunno, Alicia Tosoni, Marta Aprile, Chiara Maria Argento, Marzia Margotti, Stefania Bartolini, Enrico Franceschi","doi":"10.1007/s40487-025-00355-1","DOIUrl":"10.1007/s40487-025-00355-1","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR)-T cell therapy is emerging as a promising immunotherapeutic modality for improving clinical outcomes in high-grade gliomas. Three recent studies have demonstrated the safety and feasibility of intracranial CAR-T cell administration in patients with glioblastoma (GBM), along with preliminary evidence of rapid but transient objective responses. These findings provide a rationale for further clinical investigation of this approach.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug Utilisation of Radium-223 Under Routine Clinical Practice (DIRECT) in Europe: A Post-Authorisation Safety Study.","authors":"Rachel Weinrib, Joan Fortuny, David Martinez, Bianca Kollhorst, Ulrike Haug, Astrid Kousholt, Vera Ehrenstein, Peter Iversen, Jann Mortensen, Dianne Bosch, Malou Kuppen, Federica Pisa, Zdravko Vassilev","doi":"10.1007/s40487-025-00344-4","DOIUrl":"https://doi.org/10.1007/s40487-025-00344-4","url":null,"abstract":"<p><strong>Introduction: </strong>Radium-223 is indicated for adults with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases, without visceral metastases, who progress after at least (≥) two lines of or are ineligible for other systemic therapies (besides luteinising hormone-releasing hormone analogues). Radium-223 is contraindicated in combination with abiraterone acetate and prednisone/prednisolone. Point 2 and the contraindication above were added to the 2018 European Medicines Agency (EMA) label. In the observational cohort study reported here, we evaluated compliance with the 2018 revised label.</p><p><strong>Methods: </strong>The proportion of patients with mCRPC who initiated radium-223 in the Netherlands, Germany and Denmark was analysed descriptively before (2013-2017) and after (2019-2020) the label change, allowing ≥ 6 months of follow-up. No a priori hypotheses were evaluated.</p><p><strong>Results: </strong>A total of 1070 patients were included in this observational cohort study (before/after the label change: Netherlands [243/53]; Germany [580/71]; Denmark [60/63]). Radium-223 use with abiraterone acetate or other systemic mCRPC therapies was limited and decreased after the label change in the Netherlands and Germany; in Denmark, combined use was not observed before the label change and was observed only rarely after the label change. After the label change, radium-223 use without ≥ 2 prior lines of systemic mCRPC therapy decreased in all countries, despite remaining relatively common in the Netherlands and Germany.</p><p><strong>Conclusions: </strong>Radium-223 use in combination with abiraterone acetate or other systemic mCRPC therapies largely aligned with the 2018 EMA label change. However, after the label change, radium-223 use without ≥ 2 prior lines of systemic mCRPC therapy remained relatively common in the Netherlands and Germany, possibly because radium-223 was previously recommended as first-line treatment for frail patients, and doctors still may consider it for use in these cases. We could not assess patients' eligibility for other systemic mCRPC therapies; therefore, these findings may partly reflect radium-223 on-label use in patients with contraindications for other systemic therapies.</p><p><strong>Ema study identification number: </strong>EUPAS37163.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer.","authors":"Marina C Garassino, Ying Cheng, Delvys Rodriguez-Abreu, Silvia Novello, Julien Mazieres, Andrew G Robinson, Steven F Powell, Balazs Halmos, Jhanelle E Gray, Meihua Wang, Cong Chen, Jing Yang, Fabricio Souza, Paul Schwarzenberger, Luis Paz-Ares","doi":"10.1007/s40487-025-00350-6","DOIUrl":"https://doi.org/10.1007/s40487-025-00350-6","url":null,"abstract":"<p><strong>Introduction: </strong>Response Evaluation Criteria in Solid Tumors (RECIST) is the primary tool for assessing tumor response in solid tumors. Immunotherapy elicits unique response patterns, and assessment of their contribution to overall survival (OS) is of interest. We evaluated tumor size changes (TSC) for association with OS, evaluated whether deeper response had greater association with OS than the 30% RECIST cutoff, and quantified the contribution of objective response rate (ORR) and duration of response (DOR) to OS benefit using data from KEYNOTE-189 and KEYNOTE-407 examining first-line pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>Associations between early TSC (percentage change from baseline in sum of target lesion diameters) and OS were evaluated using recursive partitioning analyses, C-index, and time-varying receiver operating characteristic curve. Deeper response and OS associations were assessed in sensitivity analyses. Contribution of TSC, ORR, and DOR to the OS benefit of pembrolizumab plus chemotherapy (versus chemotherapy) was quantified with a proportion of treatment effect analysis. Data cutoff was May 2019.</p><p><strong>Results: </strong>In total, 1175 participants were included (KEYNOTE-189, n = 616; KEYNOTE-407, n = 559). At week 12, -30% TSC had a greater association with OS than other cutoffs, which was similar to week 12 ORR. Deeper response did not have greater association with OS than the 30% RECIST cutoff. For pembrolizumab plus chemotherapy versus chemotherapy in KEYNOTE-189, the proportion of treatment effect on OS benefit for DOR coupled with ORR was higher than ORR alone (0.57 versus 0.36) or an alternative TSC cutoff (0.57 versus 0.08 for -10%, 0.09 for -20%, and 0.20 for -30%), with similar results in KEYNOTE-407 for DOR and ORR versus ORR alone (0.92 versus 0.61) or an alternative TSC cutoff (0.92 versus 0.36, 0.43, and 0.40, respectively).</p><p><strong>Conclusions: </strong>These ad hoc exploratory analyses suggest that RECIST remains a valid assessment for metastatic NSCLC treated with immunotherapy plus chemotherapy. Early responses per RECIST criteria predicted improved OS.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, NCT02578680, NCT02775435.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144267570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"On the Horizon: A Global Multidisciplinary Perspective on Delivering Emerging Therapies for Patients with BCG-Naïve High-Risk NMIBC.","authors":"Bernadett E Szabados, Félix Guerrero-Ramos, Enrique Grande, Petros Grivas, Viktor Grünwald, Marta Carpintero Miguel, Syed A Hussain, Girish S Kulkarni, Ana Lisa Wilson, Neal D Shore, Srikala S Sridhar, Mary Hoyt, Samantha Strumeier, Jennifer Sutton, Julia Brinkmann, Rosemary E Teresi, Tilman Todenhöfer","doi":"10.1007/s40487-025-00334-6","DOIUrl":"10.1007/s40487-025-00334-6","url":null,"abstract":"<p><p>Patients with high-risk non-muscle invasive bladder cancer (NMIBC) are generally treated with transurethral resection of the bladder tumor followed by intravesical bacillus Calmette-Guérin (BCG), the current standard of care. However, recurrence or progression is common and may result in patients requiring radical cystectomy. Additionally, BCG continues to be in short supply worldwide. Therefore, there is an unmet need for new therapies that provide durable disease control and maintain quality of life. In the BCG-naïve high-risk NMIBC setting, potential new treatment options are emerging, with several regimens combining intravesical therapy with systemic PD-1 or PD-L1-directed immune checkpoint inhibitors (ICIs) currently under investigation in several Phase 3 trials. In routine clinical practice, NMIBC has traditionally been managed almost entirely by urologists. However, the introduction of systemic ICIs would likely require medical oncology expertise to help assess patients' fitness for these therapies and potentially for treatment administration and immune-related adverse event management. While multidisciplinary workflows are common practice for advanced bladder cancer, they would represent a paradigm shift in NMIBC. Based on current experience of managing patients with NMIBC across different countries and healthcare systems from our perspective as urologists, medical oncologists, and nurses, we discuss best practices for the potential integration of emerging therapies such as ICIs into the treatment of BCG-naïve high-risk NMIBC. We emphasize the need for multidisciplinary care, either through formalized multidisciplinary teams or cross-discipline collaborative workflows adapted to local needs, to ensure efficient coordination and sharing of responsibilities. Specialized nurses have the potential to play key roles across multiple aspects of patient care. We also highlight the crucial importance of effective communication across teams, increases in resourcing, and education for healthcare professionals, patients, and caregivers to enable eligible patients with high-risk NMIBC to benefit optimally from the introduction of these potential new treatment options.  Supplementary file2 (MP4 407382 kb).</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"275-291"},"PeriodicalIF":3.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12130421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144038137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survey of Health Care Providers on Social Determinants of Health and Treatment Decision-Making for Patients With HR+/HER2- Metastatic Breast Cancer.","authors":"Monique Gary, Editha Krueger, Molly Kisiel, Kimberly Demirhan, Alexandra Guarin Barajas, Joanne C Ryan","doi":"10.1007/s40487-025-00337-3","DOIUrl":"10.1007/s40487-025-00337-3","url":null,"abstract":"<p><strong>Introduction: </strong>Social determinants of health (SDOH) are a range of nonmedical factors that contribute to outcome disparities among certain groups of patients; however, little is known about how SDOH affect treatment decision-making for patients with cancer, particularly those with metastatic breast cancer (mBC). This study sought to gain insights from physicians and advanced practice providers on the impact of SDOH on practice- and patient-level cancer care decision-making with a nationwide online survey.</p><p><strong>Methods: </strong>The Social Determinants of Health in Metastatic Breast Cancer Survey was developed by the Association of Cancer Care Centers (ACCC) in partnership with Pfizer Inc, and in consultation with SDOH specialists. The 23-question survey captured experiences with SDOH-informed treatment decision-making for patients with cancer via multiple choice, Likert-scale, and free-response questions. ACCC-member physicians and advanced practice providers in the USA completed the survey between 23 January and 8 February 2024.</p><p><strong>Results: </strong>Respondents (n = 145), a majority of whom were medical oncologists (60%), represented clinics from diverse geographic regions of the USA; approximately 65% of respondents' clinics served patient populations with ≥ 10% Black, Indigenous, or People of Color. Common comprehensive cancer care services were provided by at least 59% of clinics, and SDOH factors were assessed by approximately 75% of clinics at diagnosis. Navigation services were available for patients with mBC at approximately 75% of respondents' clinics. Financial considerations (51%) and the presence of a caregiver (35%) were the most frequently cited SDOH-related factors that impacted mBC treatment decision-making.</p><p><strong>Conclusion: </strong>The surveyed ACCC-member care providers displayed a high degree of awareness regarding SDOH impacts on their practice and patients, but resource limitations were identified as barriers to comprehensive, SDOH-informed cancer care. Harnessing existing resources from local and national advocacy groups, especially navigator training programs, is an actionable, real-world solution for improving mBC care for patients facing SDOH barriers.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"429-446"},"PeriodicalIF":3.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12130359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone Metastases and Skeletal Complications: Information and Involvement of Patients with Cancer in the Treatment Pathway.","authors":"Stefania Gori, Alessandra Fabi, Giuseppe Procopio, Mario Airoldi, Alberto Zambelli, Gaetano Lanzetta, Sergio Bracarda, Jennifer Foglietta, Silvana Leo, Anna Baggi, Jean Marie Franzini, Matteo Valerio, Matteo Verzè, Fabrizio Nicolis","doi":"10.1007/s40487-025-00343-5","DOIUrl":"10.1007/s40487-025-00343-5","url":null,"abstract":"<p><strong>Introduction: </strong>Adequate information about patients with bone metastases could increase adherence to treatment and reduce or delay skeletal and dental complications. Limited data are available on patient awareness, the degree of information received, and adherence to specific treatment for bone metastases.</p><p><strong>Methods: </strong>ROPI (Rete Oncologica Pazienti Italia) conducted an anonymous survey from 1 February to 31 August 2022 among patients with bone metastases from solid tumors to evaluate their level of information and adherence to specific treatments and dental evaluations. Questionnaires were administered by oncologists or nurses at participating cancer centers.</p><p><strong>Results: </strong>Analysis of 351 questionnaires revealed that 75% of patients felt \"fairly/well\" informed about bone metastases and skeletal complications. The oncologists were the primary source of information. More than 80% of patients reported undergoing specific treatment for bone metastases (denosumab, 48%; zoledronic acid, 46%); 93% of patients received dental evaluations before starting therapy (with dental complications in only 0.3% of patients) and 78% received information about the importance of regular dental checkups. Vitamin D and calcium supplements were taken by 83% of patients. Among patients with skeletal complications (47% of patients), bone radiotherapy was the most frequent (94%).</p><p><strong>Conclusions: </strong>Most patients stated that they had received information about bone metastases, skeletal complications, and specific treatments. This could increase awareness and adherence to treatment and potentially reduce or delay skeletal and/or dental complications improving patients' quality of life and survival.</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"505-517"},"PeriodicalIF":3.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12130396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144051553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}